Quantum Genomics Raises Millions in US & Europe
Quantum Genomics recently announced it has completed a private placement with US institutional investors totalling €5.54 million. Directly following the US capital increase, the company raised an additional €3.04 million through a public offering in Europe through existing shareholders, for a total of €8.6 million.
In these two placements, the company issued 1,429,973 shares at €6.00 per share, and warrants to purchase an additional 714,986 shares at an exercise price of €7.75 per share for 30 months. The warrants, if fully exercised, would generate additional proceeds of €5.5 million. Participation in the European rights offering was open to shareholders of Quantum Genomics as of March 16, 2016.
“This capital increase is consistent with our expansion strategy, which includes the recently announced establishment of a US Clinical Advisory Board and the opening of an office in New York on March 1, 2016. The funds raised will enable us to further advance, in the US and various European countries, the Phase II clinical trials of our products for the treatment of resistant hypertension and heart failure,” said Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics.
Maxim Group LLC acted as the exclusive placement agent in the United States, and Invest Securities managed the subscriptions in France.
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure. Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes. For more information, visit www.quantum-genomics.com.
Total Page Views: 1529
